Similar articles

• Efficacy of fluoroquinolones against pathogenic oral bacteria.

  Núñez Otero V, Limeres Posse J, Carmona IT, Diz Dios P. Núñez Otero V, et al. Mini Rev Med Chem. 2009 Sep;9(10):1147-58. doi: 10.2174/138955709789055243. Mini Rev Med Chem. 2009. PMID: 19534690 Review.
• Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections.

  Kontou P, Manika K, Chatzika K, Papaioannou M, Sionidou M, Pitsiou G, Kioumis I. Kontou P, et al. Int J Antimicrob Agents. 2013 Sep;42(3):262-7. doi: 10.1016/j.ijantimicag.2013.04.028. Epub 2013 Jul 4. Int J Antimicrob Agents. 2013. PMID: 23830621
• Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.

  Scoper SV. Scoper SV. Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Adv Ther. 2008. PMID: 18836691 Review.
• Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone.

  Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. Drago L, et al. J Chemother. 2004 Feb;16(1):30-7. doi: 10.1179/joc.2004.16.1.30. J Chemother. 2004. PMID: 15077996
• [Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (Vegamox 0.5% ophthalmic solution].

  Watanabe M, Ishizuka K, Ikemoto T. Watanabe M, et al. Nihon Yakurigaku Zasshi. 2007 May;129(5):375-85. doi: 10.1254/fpj.129.375. Nihon Yakurigaku Zasshi. 2007. PMID: 17507775 Review. Japanese. No abstract available.